Bilateral panuveitis in a patient on vemurafenib BRAF inhibitor therapy for stage IV melanoma.

Purpose: To describe a case of recurrent, bilateral panuveitis caused by the BRAF proto-oncogene inhibitor vemurafenib.

Methods: Case report.

Results: A 25-year-old woman developed bilateral panuveitis and macular edema after initiating treatment with the BRAF enzyme inhibitor vemurafenib for stage IV cutaneous melanoma.